Johnson & Johnson Trading Volume Drops 55.94% Ranking 27th Despite Acquisition Boost

On April 2, 2025, Johnson & Johnson (JNJ) saw a trading volume of 15.97 billion, a significant 55.94% decrease from the previous day, ranking 27th in the day's market activity. The stock price of Johnson & Johnson rose by 1.38%.

Johnson & Johnson has completed its acquisition of Intra-Cellular Therapies, Inc., a move that is expected to bolster its leadership in the neuroscience field. This acquisition brings CAPLYTA® (lumateperone) into Johnson & Johnson's portfolio, a drug approved for the treatment of schizophrenia and bipolar depression. The deal is anticipated to add $0.7 billion in incremental sales and $0.25 in earnings per share, further strengthening Johnson & Johnson's position in the pharmaceutical industry.

This strategic acquisition aligns with Johnson & Johnson's long-term vision to enhance its neuroscience capabilities and expand its product offerings. The integration of Intra-Cellular Therapies' innovative therapies is expected to drive growth and innovation within Johnson & Johnson's neuroscience division, benefiting both the company and its shareholders in the long run.